ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Cancer Immunotherapy: A Long-Awaited Reality

Cancer Immunotherapy: A Long-Awaited Reality

At the 1-day Cancer Immunotherapy: A Long Awaited Reality Conference, representatives from biotechnology companies and research clinicians working on immunotherapies discussed the promise of combination immunotherapies in cancer.

A personalized form of immunotherapy called adoptive T-cell transfer is moving beyond a few specialized academic centers to biotechnology and pharmaceutical development.

Several companies are focusing on boosting T-cell activity against tumors by engineering human cells to produce antigens and adjuvants, which, like vaccines, can prime and modulate an immune response.

Subscribe to Cancer Immunotherapy: A Long-Awaited Reality on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.